Literature DB >> 32877567

Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.

Ashly E Jordan1,2,3, Charles M Cleland2,4, Katarzyna Wyka1, Bruce R Schackman5, David C Perlman2,6, Denis Nash1.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) incidence has increased in the worsening opioid epidemic. We examined the HCV preventive efficacy of medication-assisted treatment (MAT), and geographic variation in HCV community viral load (CVL) and its association with HCV incidence.
METHODS: HCV incidence was directly measured in an open cohort of patients in a MAT program in New York City between 1 January 2013 and 31 December 2016. Area-level HCV CVL was calculated. Associations of individual-level factors, and of HCV CVL, with HCV incidence were examined in separate analyses.
RESULTS: Among 8352 patients, HCV prevalence was 48.7%. Among 2535 patients seronegative at first antibody test, HCV incidence was 2.25/100 person-years of observation (PYO). Incidence was 6.70/100 PYO among those reporting main drug use by injection. Female gender, drug injection, and lower MAT retention were significantly associated with higher incidence rate ratios. Female gender, drug injection, and methadone doses <60 mg were independently associated with shorter time to HCV seroconversion. HCV CVLs varied significantly by geographic area.
CONCLUSIONS: HCV incidence was higher among those with lower MAT retention and was lower among those receiving higher methadone doses, suggesting the need to ensure high MAT retention, adequate doses, and increased HCV prevention and treatment engagement. HCV CVLs vary geographically and merit further study as predictors of HCV incidence.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HCV incidence; epidemics; epidemiology; geographic analysis; hepatitis C virus; injection drug use; opioid use disorder; people who use drugs

Mesh:

Substances:

Year:  2020        PMID: 32877567      PMCID: PMC7566606          DOI: 10.1093/infdis/jiz659

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  The Affordable Care Act Transformation of Substance Use Disorder Treatment.

Authors:  Amanda J Abraham; Christina M Andrews; Colleen M Grogan; Thomas D'Aunno; Keith N Humphreys; Harold A Pollack; Peter D Friedmann
Journal:  Am J Public Health       Date:  2017-01       Impact factor: 9.308

Review 2.  The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions.

Authors:  David C Perlman; Ashly E Jordan
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

3.  Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.

Authors:  Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman
Journal:  Drug Alcohol Depend       Date:  2015-04-13       Impact factor: 4.492

Review 4.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

5.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

6.  Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?

Authors:  Iuliia Makarenko; Adelina Artenie; Stine Hoj; Nanor Minoyan; Brendan Jacka; Geng Zang; Gillian Barlett; Didier Jutras-Aswad; Valerie Martel-Laferriere; Julie Bruneau
Journal:  Int J Drug Policy       Date:  2019-04-19

7.  The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative.

Authors:  Aryan Esmaeili; Ali Mirzazadeh; Meghan D Morris; Behzad Hajarizadeh; Henry S Sacks; Lisa Maher; Jason Grebely; Arthur Y Kim; Georg Lauer; Andrea L Cox; Margaret Hellard; Paul Dietze; Julie Bruneau; Naglaa H Shoukry; Gregory J Dore; Andrew R Lloyd; Maria Prins; Kimberly Page
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

8.  Determining effective methadone doses for individual opioid-dependent patients.

Authors:  Jodie A Trafton; Jared Minkel; Keith Humphreys
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

9.  Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework.

Authors:  Stephanie Popping; Manal El-Sayed; Jordan Feld; Angelos Hatzakis; Margaret Hellard; Olufunmilayo Lesi; Michael Ninburg; John Ward; Charles Boucher
Journal:  J Virus Erad       Date:  2018-07-01

10.  Estimating the prevalence of chronic hepatitis C virus infection in New York City, 2015.

Authors:  A Bocour; S K Greene; F Laraque; A Winters
Journal:  Epidemiol Infect       Date:  2018-06-22       Impact factor: 4.434

View more
  5 in total

1.  Medicaid Subscription-Based Payment Models and Implications for Access to Hepatitis C Medications.

Authors:  Samantha G Auty; Paul R Shafer; Kevin N Griffith
Journal:  JAMA Health Forum       Date:  2021-08-27

2.  Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064).

Authors:  Lisa R Metsch; Daniel J Feaster; Lauren K Gooden; Carmen Masson; David C Perlman; Mamta K Jain; Tim Matheson; C Mindy Nelson; Petra Jacobs; Susan Tross; Louise Haynes; Gregory M Lucas; Jonathan A Colasanti; Allan Rodriguez; Mari-Lynn Drainoni; Georgina Osorio; Ank E Nijhawan; Jeffrey M Jacobson; Meg Sullivan; David Metzger; Pamela Vergara-Rodriguez; Ronald Lubelchek; Rui Duan; Jacob N Batycki; Abigail G Matthews; Felipe Munoz; Eve Jelstrom; Raul Mandler; Carlos Del Rio
Journal:  Open Forum Infect Dis       Date:  2021-06-27       Impact factor: 4.423

3.  Big Events theory and measures may help explain emerging long-term effects of current crises.

Authors:  Samuel R Friedman; Pedro Mateu-Gelabert; Georgios K Nikolopoulos; Magdalena Cerdá; Diana Rossi; Ashly E Jordan; Tarlise Townsend; Maria R Khan; David C Perlman
Journal:  Glob Public Health       Date:  2021-04-11

4.  Application of machine learning algorithms for localized syringe services program policy implementation - Florida, 2017.

Authors:  Tyler S Bartholomew; Hansel E Tookes; Emma C Spencer; Daniel J Feaster
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

5.  The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures.

Authors:  Stephanie Popping; Valeria Cento; Carole Seguin-Devaux; Charles A B Boucher; Adolfo de Salazar; Eva Heger; Orna Mor; Murat Sayan; Dominique Salmon-Ceron; Nina Weis; Henrik B Krarup; Robert J de Knegt; Oana Săndulescu; Vladimir Chulanov; David A M C van de Vijver; Federico García; Francesca Ceccherini-Silberstein
Journal:  Viruses       Date:  2021-12-22       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.